Skip to Main Content

Celgene (CELG) delivered a strong first-quarter earnings report Friday and a regulatory update on its delayed multiple sclerosis drug that took the worst-case scenario off the table.

The beleaguered biotech hasn’t fixed all its problems quite yet, but Friday’s business update didn’t give investors another reason to hate them, so it feels like a win. Shares of Celgene were up 3 percent to $87.70 in morning trading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.